The Law Office of Robbins Umeda LLP Announces an Investigation of the Acquisition of Martek Biosciences Corp. by Royal DSM N.V.
December 21 2010 - 2:39PM
Business Wire
Robbins Umeda LLP has commenced an investigation into possible
breaches of fiduciary duty and other violations of state law by
members of the Board of Directors ("Board") of Martek Biosciences
Corporation ("Martek" or the "Company") (NASDAQ: MATK) in
connection with their efforts to sell Martek to Royal DSM N.V.
("DSM") (Euronext: DSM KON). The transaction will be accomplished
through an all-cash tender offer. If the transaction is completed,
Martek shareholders will receive $31.50 in cash for each share of
Martek common stock they hold. The tender offer is expected to
commence in January 2011 and is expected to close in February
2011.
Robbins Umeda LLP's investigation concerns whether Martek's
Board undertook a fair process to obtain fair consideration for all
shareholders of Martek. Specifically, our investigation concerns
whether members of the Company's Board breached their fiduciary
duties to Martek shareholders by failing to adequately shop the
Company before entering into the transaction with DSM.
If you are a shareholder of Martek, plan to continue to hold
your shares, and would like more information about your rights as a
shareholder, please contact attorney Gregory E. Del Gaizo at
800-350-6003 or by e-mail at info@robbinsumeda.com.
Robbins Umeda LLP represents individual and institutional
shareholders in derivative, direct, and class action lawsuits. The
law firm's skilled litigation teams include former federal
prosecutors, former defense counsel from top multinational
corporate law firms, and career shareholder rights lawyers. Robbins
Umeda LLP has helped its clients realize more than $1 billion of
value for themselves and the companies in which they have invested.
For more information, please go to http://www.robbinsumeda.com.
Attorney Advertising. Past results do not guarantee a similar
outcome. We invite you to contact us today to discuss your
case.
Martek (NASDAQ:MATK)
Historical Stock Chart
From Oct 2024 to Nov 2024
Martek (NASDAQ:MATK)
Historical Stock Chart
From Nov 2023 to Nov 2024